Jeena Sikho Lifecare Reports Robust Q2 FY26 Performance with 66% YoY Revenue Growth
Jeena Sikho Lifecare announced strong Q2 FY26 results with 66% YoY revenue growth, 129% EBITDA increase, and improved margins. Operational expansion and new product launches further bolster positive outlook.
The announcement details robust financial performance, substantial operational growth, and strategic initiatives like capacity expansion, new product launches, and a major technology partnership. These factors are likely to have a significant positive impact on investor confidence and the company's market valuation.
The company reported significant year-on-year and quarter-on-quarter growth across key financial metrics (revenue, EBITDA, PAT, EPS) and strong operational expansion in patient volumes and bed capacity. The strategic shift towards higher-margin private business and a new Salesforce partnership also indicate positive future prospects.
* Jeena Sikho Lifecare Limited (JSLL) reported strong financial results for Q2 FY26, with revenue from operations growing by 66% year-on-year to ₹189.85 crore, and a 9% quarter-on-quarter increase. * EBITDA surged by 129% year-on-year to ₹92.06 crore, achieving an EBITDA margin of 48% in Q2 FY26, up from 35% in Q2 FY25 and 45% in Q1 FY26. * Profit After Tax (PAT) increased by 121% year-on-year to ₹58.78 crore, with a PAT margin of 31%. * Basic Earnings Per Share (EPS) for Q2 FY26 stood at ₹4.73, marking a 121% year-on-year growth. * Operational highlights include significant patient volume growth: OPD patients increased by 67% YoY to 1.40 lakh, IPD patients grew by 57% YoY to 9,614, and Day Care volumes rose by 169% YoY to 17,154. * The company expanded its capacity by making three new hospitals operational, bringing the total operational bed capacity to over 2,220 beds, with approximately 400 additional beds under development across five facilities. * JSLL launched new products in its OTC and Medicines division, including Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, and Dr. Sukoon DS, with six more product launches planned for the remainder of the year. * A strategic partnership with Salesforce was announced to strengthen technology infrastructure and operational workflows, aiming to enhance patient care and operational efficiency. * Management noted a strategic shift towards the private business segment, which offers superior margins, further strengthening profitability and improving cash-conversion cycles. * The investor presentation for Q2 FY26 will be used during meetings with investors scheduled on November 07, 2025.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.